 |
27 Diseases |  |
27 Trials |
|
27 Trials |  |
307 News |  |
| «12345678» |
- || Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Retrospective data, Review, Journal: Intravitreal conbercept improves outcome in patients undergoing vitrectomy for proliferative diabetic retinopathy: A systematic review and meta-analysis. (Pubmed Central) - May 28, 2021
Intravitreal conbercept was associated with a more significant BCVA improvement, better intraoperative outcome, and less postoperative vitreous hemorrhage compared to no conbercept.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Comprehensive evaluation of intravitreal conbercept versus half-dose photodynamic therapy for chronic central serous chorioretinopathy. (Pubmed Central) - May 21, 2021
Half-dose PDT may show better outcome at initial phase of treatment in chronic CSC. Longer follow-up period is necessary to study for long-term effect and safety.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Short-term effects of intravitreal Conbercept injection combined with laser photocoagulation on macular edema secondary to ischemic retinal vein occlusion. (Pubmed Central) - May 21, 2021
Longer follow-up period is necessary to study for long-term effect and safety. Intravitreal Conbercept injection combined with laser photocoagulation appears to be a safe and effective treatment for ME secondary to iRVO in the short-term.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography. (Pubmed Central) - May 15, 2021
Anti-vascular endothelial growth factor treatment may have a positive effect on macular perfusion status. Furthermore, OCTA had advantages in quantifying and calculating blood flow index in the study of macular perfusion status.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Observational data, Retrospective data, Journal, Real-world evidence: Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. (Pubmed Central) - May 15, 2021
Furthermore, OCTA had advantages in quantifying and calculating blood flow index in the study of macular perfusion status. Intravitreal conbercept 0.5 mg was safe and effective for treatment of myopic CNV over 12 months in a real-world setting.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Retrospective data, Journal: Visual outcomes and complications following one-way air-fluid exchange technique for vitreous hemorrhage post vitrectomy in proliferative diabetic retinopathy patients. (Pubmed Central) - May 15, 2021
Intravitreal conbercept 0.5 mg was safe and effective for treatment of myopic CNV over 12 months in a real-world setting. This one-way air-fluid exchange procedure can effectively exchange the vitreous hemorrhage and improve visual acuity of PDR patients who develop vitreous rehemorrhage post vitrectomy without obvious complications.
- Lumitin (conbercept) / Chengdu Kanghong Biotech
[VIRTUAL] Inhibition of corneal neovascularization with rAAV-anti-VEGF in mouse corneal injury models () - May 13, 2021 - Abstract #ARVO2021ARVO_3165;
This one-way air-fluid exchange procedure can effectively exchange the vitreous hemorrhage and improve visual acuity of PDR patients who develop vitreous rehemorrhage post vitrectomy without obvious complications. Our study demonstrates the potential and relative safety of rAAV-based anti-angiogenesis therapy in the treatment of corneal neovascularization progression.
- Lumitin (conbercept) / Chengdu Kanghong Biotech
[VIRTUAL] Low-dose rAAV-mediated inhibition of VEGF can treat neovascular pathologies without inducing retinal vasculitis () - May 13, 2021 - Abstract #ARVO2021ARVO_1282;
The data suggest that rAAV-mediated expression of anti-VEGF drugs can be employed safely for the treatment of neovascular eye pathologies. However, vector design needs to be taken into consideration when determining the appropriate therapeutic dose.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Retrospective data, Journal: Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study. (Pubmed Central) - May 13, 2021
However, vector design needs to be taken into consideration when determining the appropriate therapeutic dose. PRP after IVC requires less injections but also yields similar visual and anatomic outcome comparing with PRP prior to IVC in patients with diabetic retinopathy combined with DME.
- | Lucentis (ranibizumab) / Roche, Novartis
Preclinical, Journal: The Role of Intravitreal Anti-VEGF Agents in Rabbit Eye Model of Open-Globe Injury. (Pubmed Central) - May 7, 2021
Both Ranibizumab and Conbercept inhibited epiretinal scar formation at the wound site, with Conbercept showing the greatest effect (maximal length of scar (L), L = 503 ± 82.44 μm, L = 355 ± 43.66 μm, and L = 250.33 ± 36.02 μm). Anti-VEGF treatments after OGI significantly attenuated the upregulation of growth factors and cytokines in the vitreous and prevented intravitreal proliferation and epiretinal scar formation and thus may protect against the development of posttraumatic complications such as proliferative vitreoretinopathy (PVR).
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT. (Pubmed Central) - May 5, 2021
Anti-VEGF treatments after OGI significantly attenuated the upregulation of growth factors and cytokines in the vitreous and prevented intravitreal proliferation and epiretinal scar formation and thus may protect against the development of posttraumatic complications such as proliferative vitreoretinopathy (PVR). The external limiting membrane status and hyperreflective foci >20 at baseline could be good predictors for short-term visual outcome, whereas the central subfield thickness and ellipsoid zone status at baseline and their changes over time may predict visual improvement in patients with retinal vein occlusion macular edema after intravitreal conbercept injection.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Retrospective data, Review, Journal: Clinical efficacy and acceptability of panretinal photocoagulation combined with conbercept for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis. (Pubmed Central) - May 5, 2021
It was hypothesized that intravitreal conbercept plus PRP was more effective than PRP alone. 10.17605/OSF.IO/HCQ2S.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Efficacy of Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema: A Bayesian Network Analysis. (Pubmed Central) - May 4, 2021
This conclusion may provide clinical evidence to guide treatment decisions. However, more high-quality randomized controlled trials will be necessary to further confirm this.
- Lumitin (conbercept) / Chengdu Kanghong Biotech
[VIRTUAL] rAAV-Mediated Inhibition of Vascular Endothelial Growth Factor for the Treatment of Retinal Vascular Pathologies without Causing Vasculitis () - Apr 30, 2021 - Abstract #ASGCT2021ASGCT_327;
Here, we test the safety and efficacy of delivering the anti-VEGF drug Conbercept (KH902) with rAAV vectors in two mouse models of vascular pathology...Importantly, low viral doses were still able to reduce edemas and lesion size without causing any vascular sheathing pathology. The data suggest that rAAV-mediated expression of anti-VEGF drugs can be employed safely for the treatment of neovascular eye pathologies.
- Lumitin (conbercept) / Chengdu Kanghong Biotech
[VIRTUAL] Efficacious, Safe, and Stable Inhibition of Corneal Neovascularization with rAAV-KH902 in a Mouse Model of Corneal Alkali injury () - Apr 30, 2021 - Abstract #ASGCT2021ASGCT_104;
Our study demonstrates the potential and relative safety of rAAV-based, long-term anti-angiogenesis therapy with KH902 in the treatment of CoNV.# The authors contributed equally to this work. * Corresponding authors.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Evaluation of Microvascular Structure Changes after Conbercept Treatment on Macular Edema Secondary to Retinal Vein Occlusion. (Pubmed Central) - Apr 29, 2021
Conbercept had a significant effect on treatment of RVO with macular edema. A more profound effect was achieved in the iRVO group on visual improvement and FAZ reduction in the non-iRVO group after conbercept treatment.
- ||| RC28-E / Rongchang Pharma
Enrollment open: Evaluation of RC28-E Injection in Diabetic Macular Edema (clinicaltrials.gov) - Apr 27, 2021
P2, N=150, Recruiting, Sponsor: RemeGen
A more profound effect was achieved in the iRVO group on visual improvement and FAZ reduction in the non-iRVO group after conbercept treatment. Not yet recruiting --> Recruiting
- | Journal: Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. (Pubmed Central) - Apr 10, 2021
Nine other upcoming agents have at least produced results in the 2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China. (Pubmed Central) - Apr 7, 2021
Very low EO rates were seen in mainland China using a standardized sterile technique in an OR. However, EO could not be completely avoided.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal, Real-world evidence: Real-world outcomes of two-year Conbercept therapy for diabetic macular edema. (Pubmed Central) - Mar 23, 2021
However, EO could not be completely avoided. IVC is safe and effective for the treatment of DME.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Intracameral anti-VEGF injection for advanced neovascular glaucoma after vitrectomy with silicone oil tamponade. (Pubmed Central) - Mar 23, 2021
Intracameral injection of conbercept is safe and effective in the treatment of patients with advanced NVG after vitrectomy with silicone oil tamponade. Within 2d after injection is the optimal time window for trabeculectomy, which can maximally reduce the risk of perioperative hyphema.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy. (Pubmed Central) - Mar 19, 2021
Furthermore, the levels of VEGF-A and -B in the vitreous humor of patients dropped significantly in the drug group compared with those in the surgical group. These results provide theoretical clinical support for the preoperative application of conbercept for patients with PDR.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Quantification of Diabetic Retinopathy Lesions in DME Patients With Intravitreal Conbercept Treatment Using Deep Learning. (Pubmed Central) - Mar 13, 2021
[Ophthalmic Surg Lasers Imaging Retina. 2020;51:95-100.].
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Assessment of conbercept therapy for high myopia macular neovascularization by optical coherence tomography angiography. (Pubmed Central) - Mar 9, 2021
Our results suggest that conbercept can effectively and safely improve BCVA and reduce CMT in patients with myopic MVN (mMNV). OCTA can be used to observe MNV area, blood flow area, and MNV morphological changes after treatment with conbercept, thus providing a reference for treatment follow-up.
- |||| RC28-E / Rongchang Pharma
New P2 trial: Evaluation of RC28-E Injection in Diabetic Macular Edema (clinicaltrials.gov) - Mar 3, 2021
P2, N=150, Not yet recruiting, Sponsor: RemeGen
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Rapid progression of high-risk proliferative diabetic retinopathy induced by insulin intensive therapy: A case report. (Pubmed Central) - Feb 27, 2021
Insulin IT for untreated proliferative diabetic retinopathy (PDR) patients can cause severe and irreversible consequences, so for such patients, the conservative treatment for glycemic control may be much safer. But if insulin IT is inevitable, the patient should undergo PRP promptly before the IT, and close eye monitoring during the IT is also essential.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema. (Pubmed Central) - Feb 26, 2021
There was no significant difference in IOP and flare between the two groups at all following times. In patients with DME, undergoing a cataract surgery combined with intravitreal injection of conbercept is safe and effective for visual improvement and CMT declination with relatively fewer IOP and flare fluctuation.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Trial completion date, Trial primary completion date: Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Feb 25, 2021
P=N/A, N=226, Enrolling by invitation, Sponsor: Sun Yat-sen University
In patients with DME, undergoing a cataract surgery combined with intravitreal injection of conbercept is safe and effective for visual improvement and CMT declination with relatively fewer IOP and flare fluctuation. Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2022
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Retrospective data, Review, Journal: Effects of Novel Anti-VEGF Agents with Intravitreal Conbercept in Diabetic Retinopathy: A Systematic Review and Meta-Analysis. (Pubmed Central) - Feb 25, 2021
To evaluate the efficacy and safety of intravitreal conbercept (IVC) for diabetic retinopathy (DR) compared with intravitreal triamcinolone acetonide (IVTA)...Patients with IVC treatments acquired better self-care, mobility, social, and mental scores compared with IVTA (P < 0.001). Current evidence shows that IVC has better effects and safety than IVTA in treating DR, and it can significantly enhance the QoL of patients with DR.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV. (Pubmed Central) - Feb 12, 2021
The combination group required significantly fewer injections than the IVC monotherapy group (3.09 ± 0.89 vs. 3.67 ± 0.74, P = 0.006). Conbercept monotherapy significantly improved visual acuity and effectively regressed polyps during 6-month follow-up time in the treatment of PCV.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal, Heterogeneity: Site-specific and Quantitative N-glycan Heterogeneity Analysis of the Charge Isomers of an Anti-VEGF Recombinant Fusion Protein by High-resolution 2-dimensional Gel Electrophoresis and Mass Spectrometry. (Pubmed Central) - Feb 11, 2021
Conbercept is a multiglycosylated recombinant fusion protein drug approved for the treatment of age-related macular degeneration (AMD)...Finally, the quantitation of site-specific N-glycoforms in each of the 2-DE resolved spots were performed, and the results showed that the sialylaion tends to increase for gel spots located in the acidic regions. This study provides an effective approach to separate the charge isomers of the heavily glycosylated protein drugs, and to quantitatively explore the site-specific N-glycans dynamics along with the different charge isomers.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Long-Term Efficacy of Intravitreal Conbercept Injection in the Treatment of Idiopathic Choroidal Neovascularization. (Pubmed Central) - Feb 9, 2021
This study provides an effective approach to separate the charge isomers of the heavily glycosylated protein drugs, and to quantitatively explore the site-specific N-glycans dynamics along with the different charge isomers. Intravitreal injection of conbercept shows favorable effectiveness in the treatment of idiopathic CNV during a long-term period of follow-up.
- | Beovu (brolucizumab-dbll) / Novartis, faricimab (RG7716) / Roche, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: HIGHLIGHTS OF ADVANCES IN MEDICAL RETINA FROM THE VIRTUAL WORLD OPHTHALMOLOGY CONGRESS 2020. (Pubmed Central) - Feb 3, 2021
Medical retina continues to be a rapidly advancing field within ophthalmology with new research findings having great implications for treatment burden and service delivery. This report summaries the highlights of advances within the medical retina subspecialty from free papers in WOC 2020.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy. (Pubmed Central) - Jan 23, 2021
This report summaries the highlights of advances within the medical retina subspecialty from free papers in WOC 2020. Seven days and 14 days of preoperative IVC are equally efficient and safe for the vitrectomy of severe PDR patients through decreasing vitreous VEGF concentrations, intraoperative bleeding rate and total surgical times.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress. (Pubmed Central) - Jan 14, 2021
Ki67 immunofluorescence staining showed that conbercept inhibited endothelial cell proliferation in retina of PDR mice. In conclusion, conbercept significantly inhibited the angiogenesis, inflammation and oxidative response in PDR mice, and these findings further reveals the molecular mechanisms of conbercept in treating PDR.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Retrospective data, Journal: Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study. (Pubmed Central) - Jan 7, 2021
In conclusion, conbercept significantly inhibited the angiogenesis, inflammation and oxidative response in PDR mice, and these findings further reveals the molecular mechanisms of conbercept in treating PDR. No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Response to Comment on: Quantification of anterior chamber reaction after intravitreal injections of conbercept and ranibizumab: a pilot study. (Pubmed Central) - Jan 6, 2021
No abstract available No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Comment on: 'Quantification of anterior chamber reaction after intravitreal injections of conbercept and ranibizumab: a pilot study'. (Pubmed Central) - Jan 6, 2021
No abstract available No abstract available
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Three-year follow-up of Coats disease treated with conbercept and 532-nm laser photocoagulation. (Pubmed Central) - Jan 5, 2021
No abstract available Intravitreal injection of conbercept combined with 532-nm laser photocoagulation may be a feasible treatment for Coats disease in adult patients.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Proteomic analysis of anti-angiogenic effects by conbercept in the mice with oxygen induced retinopathy. (Pubmed Central) - Dec 22, 2020
Our studies reveal that many novel proteins are differentially regulated by conbercept. The new insights may warrant a valuable resource for conbercept treatment.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study. (Pubmed Central) - Dec 18, 2020
The new insights may warrant a valuable resource for conbercept treatment. In this pilot study, the effect of IVC injection in reducing the incidence of postoperative VH after diabetic vitrectomy at the end of vitrectomy was not shown.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity. (Pubmed Central) - Dec 18, 2020
We observed that IVC 0.25 mg in ROP patients suppressed the circulating levels of VEGF-A and VEGF-D as of 1 week after injection, and these growth factor levels returned to baseline at 4 weeks. No significant differences were observed in the serum levels of the other cytokines between baseline and 1 or 4 weeks after IVC.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Clinical data, Journal: Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration. (Pubmed Central) - Dec 16, 2020
During the follow-up, there were no serious adverse reactions or ocular complications. This study reveals that intravitreal injection of conbercept using 3 + Q3M regimen has certain advantages than 1 + PRN regimen in extending drug delivery interval, improving patient's vision, and reducing CRT.
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Efficacy of conbercept combined with panretinal photocoagulation in the treatment of proliferative diabetic retinopathy. (Pubmed Central) - Dec 16, 2020
Within-group analysis indicated a significant decrease in NV leakage at month 3 and month 6 in both groups, and a significant increase in BCVA at 1 month in the combination group. In summary, the combination of intravitreal injection of conbercept and PRP can significantly reduce the NV of PDR patients and achieve better BCVA during the drug's lifespan compared with PRP alone.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial, Surgery: Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema (clinicaltrials.gov) - Dec 16, 2020
P=N/A, N=40, Not yet recruiting, Sponsor: Eye & ENT Hospital of Fudan University
- | Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Comparison of intravitreal injection of conbercept and triamcinolone acetonide for macular edema secondary to branch retinal vein occlusion. (Pubmed Central) - Nov 22, 2020
IVC could maintain or improve BCVA and reduce CRT for a longer time and have longer retreatment interval than IVTA. In addition, patients treated with IVTA are more susceptible to IOP elevation and cataract progression.
- | Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Proteomic Study of Aqueous Humor and Its Application in the Treatment of Neovascular Glaucoma. (Pubmed Central) - Nov 18, 2020
The present experiment provided a comprehensive AH proteome analysis and expanded the profile of human AH proteome. The differential AH proteomic analysis of NVG treatment indicated that AH proteome can reflect the pathophysiological changes in drug intervention.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Enrollment open: Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE) (clinicaltrials.gov) - Nov 17, 2020
P=N/A, N=50, Recruiting, Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
The differential AH proteomic analysis of NVG treatment indicated that AH proteome can reflect the pathophysiological changes in drug intervention. Not yet recruiting --> Recruiting
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial: Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE) (clinicaltrials.gov) - Nov 12, 2020
P=N/A, N=50, Not yet recruiting, Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
- || Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy. (Pubmed Central) - Oct 31, 2020
Not yet recruiting --> Recruiting An intravitreal injection of conbercept after vitrectomy improved visual acuity and seemed to reduce the recurrence of VH resulting in prompt visual recovery in the PDR patients.